Project description:Methylating agents of SN1 type constitute a widely used class of anticancer drugs, the effect of which on human non-small-cell lung cancer (NSCLC) has not been adequately studied. We thus studied the effect of N-methyl-N-nitrosourea (MNU), a model SN1 methylating agent, on two human NSCLC cell lines: A549 (p53wt) and H157 (p53null). We investigated the mechanism of MNU-induced cell death through a time course gene expression profiling study, 24, 48 and 72h following treatment.
Project description:Methylating agents of SN1 type constitute a widely used class of anticancer drugs, the effect of which on human non-small-cell lung cancer (NSCLC) has not been adequately studied. We thus studied the effect of N-methyl-N-nitrosourea (MNU), a model SN1 methylating agent, on two human NSCLC cell lines: A549 (p53wt) and H157 (p53null). We investigated the mechanism of MNU-induced cell death through a time course gene expression profiling study, 24, 48 and 72h following treatment. Two human NSCLC cell lines (A549, H157) were treated with MNU or DMSO for 24h, 48h, or 72h. 34 total samples were analyzed.
Project description:Cell lines play an important role for studying tumor biology and novel therapeutic agents. We demonstrated that cell lines represent a useful and reliable in vitro system for studying basic mechanisms in lung cancer. Moreover, we presented 3 novel, comprehensively characterized SCC cell lines. Establishment and Comparative Characterization of Three Non-Small Cell Lung Cancer Cell Lines and Their Corresponding Tumor Tissue
Project description:To examine the function of Regnase-1 in non-small cell lung cancer, we compared mRNA expression between WT and ZC3H12A knockout cells using two different non-small cell lung cancer cell lines.
Project description:Immune checkpoint inhibitors are increasingly used in combination with chemotherapy for treatment of non-small cell lung cancer, yet the success of combination therapies is relatively limited. Thus, more detailed insight regarding the tumour molecular markers that may affect the responsiveness of patients to therapy is required. Here, we set out to explore the proteome of two lung adenocarcinoma cell lines (HCC-44 and A549) treated with cisplatin, pemetrexed, durvalumab, and the corresponding mixtures to establish the differences in post-treatment protein expression that can serve as markers of chemosensitivity or resistance.
Project description:This study compares the outcomes and safety of two standard treatment options called microwave ablation and surgical wedge resection in patients with non-small cell lung cancer, sarcoma and colorectal cancer that has spread to other parts of the body (metastatic). Microwave ablation is designed to kill tumor cells by heating the tumor until the tumor cells die. A wedge resection is a procedure that involves the surgical removal of a small, wedge-shaped piece of lung tissue to remove a small tumor or to diagnose lung cancer. Comparing these two treatment options may help researchers learn which method works better for the treatment of non-small cell lung cancer, metastatic sarcoma, and metastatic colorectal cancer.
Project description:Transcriptional profiling of two human lung cancer cell lines, DMS-273 (small cell lung cancer) and NCI-H1437 (non-small cell lung cancer), stably transfected either with innocuous scrambled shRNAs or SETDB1-specific.The objective was to identify global gene expression changes due to the depletion of the H3K9me3 methyltransferase SETDB1.
